Treatment with crizotinib achieves 60% response rate. However, crizotinib showed no improvement on overall survival compared to chemotherapy. This may be due to the fact that there was a 70% crossover rate to crizotinib in patients treated initially with chemotherapy. Also, patients who tested negative for<unk> /ALK fusion had a response rate to crizotinib of up to 35%.
EML4-ALK positive lung cancer
Limited-stage small cell lung carcinoma
Salivary gland–like carcinoma of the lung
complications of Mesothelioma
Thymoma with immunodeficiency
Combined small-cell lung carcinoma
Waldenström macroglobulinemia
Atypical pulmonary carcinoid tumour